AC220-A-U302 (QUANTUM-FIRST) (FL)

AC220-A-U302 (QUANTUM-FIRST) (FL)

A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)


Study treatments


Inclusion criteria


Exclusion criteria


Participating sites

Link